CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Eli Lilly and Company v. TWi Pharmaceuticals, Inc.

1:17-cv-00174

Overview

Case Number 1:17-cv-00174
Filing Date 2017-02-17
Status Terminated
Termination Date 2017-05-18
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

TWi Pharmaceuticals USA, Inc. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

TWi Pharmaceuticals, Inc. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Plaintiff

Acrux DDS Pty Ltd. Operating Company

Represented By

2 Attorneys Listed

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Maryellen Noreika

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Eli Lilly Export S.A. Operating Company

Represented By

2 Attorneys Listed

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Maryellen Noreika

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Eli Lilly and Company Operating Company

Represented By

2 Attorneys Listed

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Maryellen Noreika

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 5 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts 2 proceedings
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (5): πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (2 found):
U.S. Courts: 2
U.S. District Court 2014-12-11
1:14-cv-01474

Eli Lilly and Company v. Amneal Pharmaceuticals LLC

Asserted Patent
Status: DED
U.S. District Court 2013-05-24
1:13-cv-00851

ELI LILLY AND COMPANY v. PERRIGO COMPANY

Asserted Patent
Status: INSD
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

5 Patents

There are 5 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US8435944
Method and composition for transdermal drug delivery
Filed: 2006-06-02
Issued: 2013-05-07
Active (0.9 yrs remaining) +482d PTA
Expires: 2027-09-27
US8993520
Method and composition for transdermal drug delivery
Filed: 2010-06-25
Issued: 2015-03-31
Active (3.6 yrs remaining)
Expires: 2030-06-25
US9180194
Method and composition for transdermal drug delivery
Filed: 2014-10-08
Issued: 2015-11-10
Active (7.9 yrs remaining)
Expires: 2034-10-08
US8419307
Spreading implement
Filed: 2012-05-04
Issued: 2013-04-16
Active (5.5 yrs remaining)
Expires: 2032-05-04
US8177449
Spreading implement
Filed: 2007-02-26
Issued: 2012-05-15
Active (4.1 yrs remaining) +1386d PTA
Expires: 2030-12-13

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Active Threat

Active Threat β€” Patent is within enforceable statutory term; injunctive relief viable.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+482 days) / In re Cellect scrutiny applies.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. 4th Year Maintenance Fee Paid (8th Year Window Upcoming).

Docket Entries

(13 total)
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed against TWi Pharmaceuticals USA, Inc., TWi Pharmaceuticals, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2087367.) - filed by Eli Lilly and Company, Eli Lilly Export S.A., Acrux DDS Pty Ltd. (Attachments: # 1 Exhibit A-G, # 2 Civil Cover Sheet)(ceg) (Entered: 02/17/2017)

Entry #1 • 2017-02-17
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (ceg) (Entered: 02/17/2017)

Entry #2 • 2017-02-17
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 1/6/2017. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 7/6/2019. (ceg) (Entered: 02/17/2017)

Entry #3 • 2017-02-17
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,435,944 B2; 8,993,520 B2; 9,180,194 B2; 8,419,307 B2; 8,177,449 B2. (ceg) (Entered: 02/17/2017)

Entry #4 • 2017-02-17
1

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Eli Lilly and Company for Eli Lilly Export S.A.; Corporate Parent Acrux Limited for Acrux DDS Pty Ltd. filed by Acrux DDS Pty Ltd., Eli Lilly Export S.A., Eli Lilly and Company. (ceg) (Entered: 02/17/2017)

Entry #5 • 2017-02-17
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc